证券代码：603811 证券简称：诚意药业 公告编号：2023-013 浙江诚意药业股份有限公司 关于参加沪市主板生物医药行业上市公司 2022 年年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 05 日(星期五) 至 05 月 11 日(星期四)16:00 前登 录上证路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 office@chengyipharma.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）已于 2023 年 04 月 26 日发 布 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度的经营 成果、财务状况，同时更加充分地向投资者展示生物医药行业发展情况，公司计 划于 2023 年 05 月 12 日 上午 10:00-11:00 参加沪市主板医药行业上市公司 2022 年年报集体业绩说明会，就投资者关心的问题进行交流。 一、 说明 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥147,830,388.05, representing a decrease of 7.40% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥39,749,555.71, an increase of 37.44% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥38,805,216.40, up by 25.50% compared to the previous year[6]. - The net profit for Q1 2023 was CNY 39,622,334.78, representing a 37% increase compared to CNY 28,958,813.98 in Q1 2022[21]. - Operating profit for Q1 2023 reached CNY 41,796,167.73, up 24% from CNY 33,595,681.95 in the same period last year[21]. - The company reported a total comprehensive income of CNY 39,623,926.08 for Q1 2023, compared to CNY 28,943,664.77 in Q1 2022, indicating a 37% growth[22]. Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.17, representing a growth of 41.67%[6]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.17, up from CNY 0.12 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥47,267,096.86, reflecting a 39.42% increase year-on-year[6]. - Cash flow from operating activities showed a net increase of CNY 47,267,096.86, compared to CNY 33,901,895.37 in the previous year, marking a 39% improvement[26]. - Cash and cash equivalents at the end of Q1 2023 totaled CNY 295,962,413.46, a significant increase from CNY 77,856,033.89 at the end of Q1 2022[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,815,716,832.96, an increase of 5.62% from the end of the previous year[6]. - Current assets as of March 31, 2023, totaled CNY 508,170,893.23, an increase of 16.4% from CNY 436,837,586.65 at the end of 2022[16]. - Non-current assets amounted to CNY 1,307,545,939.73, up from CNY 1,282,255,938.30 at the end of 2022[17]. - Total liabilities were CNY 685,161,016.86, compared to CNY 628,161,634.93 at the end of 2022, indicating a rise of 9.1%[18]. - Shareholders' equity attributable to the parent company was ¥1,127,636,203.30, up by 3.65% compared to the previous year[6]. - Shareholders' equity as of March 31, 2023, was CNY 1,130,555,816.10, an increase from CNY 1,090,931,890.02 at the end of 2022[18]. Borrowings and Financing - The company experienced a 38.83% increase in cash and cash equivalents, primarily due to increased bank borrowings[9]. - The company reported a significant increase of 126.94% in short-term borrowings, attributed to increased bank loans[9]. - Short-term borrowings increased significantly to CNY 173,602,852.77 from CNY 76,498,172.22 at the end of 2022, marking a rise of 127.5%[17]. - The company raised CNY 190,000,000.00 through borrowings in Q1 2023, compared to CNY 53,649,744.44 in the same period last year, indicating a substantial increase in financing activities[27]. Operating Costs and R&D - Total operating costs for Q1 2023 were CNY 122,646,292.57, down 2.3% from CNY 126,228,137.67 in Q1 2022[20]. - Operating costs included CNY 52,009,448.21 in cost of goods sold, which increased by 12.0% from CNY 46,376,303.16 in the previous year[20]. - Research and development expenses decreased by 30.57%, mainly due to reduced material costs and outsourced R&D expenses[10]. - The company incurred R&D expenses of CNY 8,275,164.89 in Q1 2023, down from CNY 11,918,349.97 in the same quarter last year, reflecting a 30% decrease[21]. Investment Activities - The total cash outflow from investing activities was CNY 29,010,001.14 in Q1 2023, down from CNY 88,883,426.86 in Q1 2022, showing a reduction of 67%[26].

Financial Performance - The company's operating revenue for 2022 was approximately ¥654.97 million, a decrease of 5.62% compared to ¥693.96 million in 2021[22]. - The net profit attributable to shareholders for 2022 was approximately ¥161.58 million, down 5.39% from ¥170.80 million in 2021[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥139.98 million, a decrease of 10.45% from ¥156.31 million in 2021[22]. - The cash flow from operating activities for 2022 was approximately ¥165.94 million, an increase of 15.65% compared to ¥143.49 million in 2021[22]. - The total assets at the end of 2022 were approximately ¥1.72 billion, an increase of 29.99% from ¥1.32 billion at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.09 billion, up 10.30% from ¥986.31 million at the end of 2021[22]. - Basic earnings per share for 2022 were ¥0.69, a decrease of 5.48% from ¥0.73 in 2021[23]. - The weighted average return on equity for 2022 was 15.66%, down 2.8 percentage points from 18.46% in 2021[23]. Revenue and Sales - The decline in operating revenue was primarily due to market factors affecting sales of products such as calming and brain-nourishing agents, diuretics, vitamins, and intermediates[23]. - Domestic sales accounted for CNY 628.46 million, a decline of 4.60%, while international sales fell by 28.53% to CNY 24.79 million[50]. - The company achieved over 41% market share in nine provinces for its main product, Glucosamine Hydrochloride Capsules, after winning a national procurement bid[32]. - The production of joint drugs reached 121,475.70 million units, an increase of 16.97% compared to the previous year, while sales were 120,698.31 million units, up by 15.45%[53]. - The sales of diuretic drugs decreased by 39.30% to 494.40 million units, with a sales volume of 573.92 million units, down by 20.42%[54]. - The company reported a significant decline in sales of sedative and brain-nourishing drugs, with a sales volume drop of 92.55% to 2,707.45 kg[54]. Research and Development - The company has 17 new products under research, with key products like Aspartate and Ornithine approved[33]. - The total R&D expenditure amounted to 44,304,378.52 yuan, representing 6.76% of total revenue, with a year-on-year increase of 11.56% in R&D expenses[62]. - The company is committed to continuous product research and development, focusing on anti-tumor, circulatory system, and liver protection drugs to expand its product line[41]. - The company is focusing on the consistency evaluation of 10 oral solid preparations, with key products like glucosamine hydrochloride capsules approved[102]. - The company has ongoing research projects for various chemical drugs aimed at treating conditions such as osteoarthritis, dehydration from diarrhea, and chronic hepatitis B[82]. Product Development and Innovation - The company launched four new health food products, aiming to drive sales growth through multi-channel promotion[33]. - The company has developed marine biological pharmaceutical products, primarily focusing on glucosamine hydrochloride capsules (Weiergu), with a market share of over 41% in nine provinces and cities after winning the first bid in the national centralized procurement in August 2020[35]. - The company is focusing on developing treatments for respiratory diseases and viral infections, reflecting a strategic alignment with current healthcare needs[82]. - The company has a pipeline of new products, including those targeting severe infections and heart failure, showcasing its commitment to expanding its therapeutic offerings[82]. Market Strategy and Expansion - The company plans to expand its market presence through the introduction of new drugs and technologies, focusing on therapeutic areas such as joint diseases and viral infections[70]. - The company is expanding its production capabilities with the acquisition of Fujian Huakang Pharmaceutical Co., enhancing its supply chain for key products[44]. - The company is focusing on marine pharmaceuticals, leveraging its location in Wenzhou to develop marine-based drugs[44]. - The company is actively involved in the procurement process, with significant volumes for drugs like Torasemide Injection, which had a procurement volume of 3,853,901 units[75]. Corporate Governance and Compliance - The company has established a robust governance structure to ensure compliance with laws and protect shareholder rights, with no reported issues requiring regulatory remediation[108]. - The board of directors operates independently, ensuring no undue influence from the controlling shareholder, maintaining operational autonomy[109]. - The company has implemented strict information disclosure protocols to enhance transparency and prevent insider trading, safeguarding shareholder interests[110]. - The company is committed to continuous improvement in corporate governance and internal control mechanisms to promote sustainable development[110]. Environmental and Social Responsibility - The company is committed to sustainable development and has implemented pollution prevention measures in line with clean production principles[151]. - The company has ongoing projects, including a marine biopharmaceutical manufacturing project with an annual production capacity of 1000 tons of super fish oil EPA[155]. - The company made a total charitable contribution of 300,000 RMB for public welfare projects during the reporting period[162]. - The company has established a feasible emergency response plan for environmental incidents in November 2022, which was approved by the local environmental authority[157]. Shareholder and Executive Management - The total number of shares held by the chairman, Yan Yiyi, remained unchanged at 55,137,200 shares, with a pre-tax compensation of 1.0466 million yuan[113]. - The total number of shares held by director Qiu Kerong decreased by 600,000 shares, ending the year with 1,908,800 shares, with a pre-tax compensation of 420,100 yuan[113]. - The total pre-tax compensation for all executives during the reporting period amounted to 7.8321 million yuan[114]. - The company appointed Zhao Chunjian as the new general manager and made several changes to the executive team, including the appointment of new vice presidents and a financial director[114]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[120]. - New product launches are expected to contribute an additional 200 million CNY in revenue, with a focus on innovative healthcare solutions[119]. - The company plans to increase its marketing budget by 20% to support brand awareness and customer engagement initiatives[120].

Financial Performance - The company's operating revenue for Q3 2022 was ¥158,062,744.48, representing a decrease of 4.70% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,576,202.24, down 5.47% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,221,530.94, a decrease of 5.62% compared to the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.16, reflecting a decline of 5.88% year-on-year[6] - Total operating revenue for the first three quarters of 2022 was CNY 476,221,538.79, a decrease of 9.1% compared to CNY 523,732,179.68 in the same period of 2021[19] - Net profit for the third quarter of 2022 was CNY 102,486,877.63, a decline of 13.5% from CNY 118,457,818.07 in the same quarter of 2021[20] - Basic and diluted earnings per share for the third quarter of 2022 were both CNY 0.44, down from CNY 0.51 in the same quarter of 2021[21] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥1,596,670,427.54, an increase of 20.73% from the end of the previous year[6] - The company's total assets as of September 30, 2022, amount to CNY 1,596,670,427.54, an increase from CNY 1,322,493,361.66 at the end of 2021[16] - Current assets total CNY 404,722,929.22, up from CNY 287,797,305.90 in the previous year[16] - Total liabilities have increased to CNY 564,438,463.48 from CNY 323,616,586.46[17] - The company has a total equity of CNY 1,032,231,964.06 as of September 30, 2022[17] - The short-term borrowings amount to CNY 101,355,636.10, an increase from CNY 86,362,967.36[16] - The long-term borrowings have significantly increased to CNY 263,592,900.95 from CNY 59,627,951.45[17] Cash Flow - The cash flow generated from operating activities for the year-to-date was ¥106,729,566.50, showing an increase of 16.37%[6] - Cash flow from operating activities for the first three quarters of 2022 was CNY 106,729,566.50, an increase of 16.4% compared to CNY 91,717,153.63 in the same period of 2021[24] - The company received CNY 485,055,716.42 in cash from operating activities during the first three quarters of 2022, compared to CNY 515,579,877.56 in the same period of 2021[24] - Cash inflow from financing activities totaled $390,265,237.08, compared to $83,107,452.81 in the previous year, marking a significant increase[25] - Net cash flow from financing activities was $194,780,298.44, a turnaround from a negative cash flow of -$29,707,148.75 in the same quarter last year[25] - Cash and cash equivalents at the end of the period reached $195,984,125.00, up from $99,047,594.61 year-over-year, indicating a strong liquidity position[25] - The net increase in cash and cash equivalents for the quarter was $114,583,665.66, compared to $26,787,024.31 in the same quarter last year, showcasing improved cash generation[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,754[12] - The largest shareholder, Yan Yiyi, holds 55,137,200 shares, representing 23.58% of total shares[12] Investment and Expenses - The company is investing in a marine biopharmaceutical manufacturing project, which has led to increased capital expenditures[10] - Research and development expenses for the first three quarters of 2022 were CNY 35,003,808.66, an increase of 18.2% from CNY 29,531,472.54 in the previous year[19] - The company reported a total investment income of CNY 35,106,827.77 for the first three quarters of 2022, up from CNY 27,366,321.15 in the same period of 2021[19] Foreign Exchange and Other Impacts - The company experienced a foreign exchange loss of CNY 3,547,000.00 in the third quarter of 2022[20] - The impact of exchange rate fluctuations on cash and cash equivalents was a positive $392,960.59, contrasting with a negative impact of -$448,695.05 last year[25]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 318,158,794.31, a decrease of 11.10% compared to CNY 357,867,640.40 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 64,955,828.37, down 17.09% from CNY 78,349,045.35 year-on-year[18]. - The basic earnings per share decreased to CNY 0.28, down 17.65% from CNY 0.34 in the same period last year[19]. - The weighted average return on net assets was 6.44%, a decrease of 2.23 percentage points compared to 8.67% in the previous year[19]. - The decline in operating revenue was primarily due to the impact of the Shanghai pandemic, which affected sales[20]. - The net profit decline was also attributed to lower sales and underutilization of production at the subsidiary Jiangsu Chengyi, although net profit increased by 10.85% in the second quarter as the pandemic improved[20]. - The company reported a non-recurring loss of -4,619,000.00, primarily due to losses unrelated to normal business operations[22]. - The company achieved operating revenue of 318.16 million yuan, a decrease of 11.10% compared to the same period last year[34]. - Net profit attributable to shareholders was 64.96 million yuan, down 17.09% year-on-year, but showed a 10.85% increase in the second quarter as the pandemic situation improved[34]. Cash Flow and Assets - The net cash flow from operating activities increased by 31.96% to CNY 71,293,439.80, compared to CNY 54,027,637.57 in the previous year[18]. - The total assets at the end of the reporting period were CNY 1,536,858,503.24, reflecting a 16.21% increase from CNY 1,322,493,361.66 at the end of the previous year[18]. - The company reported a significant increase in cash and cash equivalents, reaching CNY 177,645,518.45, which is 113.21% higher than CNY 83,320,641.99 at the end of the previous year[43]. - The company's total assets at the end of the current period amounted to CNY 1,537,000,000, reflecting a significant increase from the previous year[43]. - The company reported a total of ¥85,971,661.34 in other payables, up from ¥62,943,714.24, indicating a growth of approximately 36.6%[108]. Research and Development - The company has 4 national new drug varieties, including 3 Class II new drugs and 1 Class IV new drug[28]. - The company has 13 invention patents and 21 utility model patents, indicating a strong focus on R&D[28]. - Research and development expenses rose by 24.51% to CNY 24,898,300.92, compared to CNY 19,996,262.19 in the previous year[40]. - The company continues to develop high-end small varieties of "marine drugs" and "medications for major diseases," with a focus on products like glucosamine hydrochloride, which has multiple specifications[34]. - The company has 11 new products under research and has successfully submitted supplementary materials for quality enhancement of existing raw materials, including glucosamine hydrochloride and vitamin K1[37]. Market Position and Strategy - The company holds 72 drug production approval numbers, with 41 products included in the national medical insurance directory[28]. - The main product, Glucosamine Hydrochloride Capsules, has achieved over 41% market share in 9 provinces and cities after winning the national procurement bid[27]. - The market for the company's main products, including Glucosamine Hydrochloride and Torasemide, is steadily growing due to their recognized efficacy[27]. - The company plans to expand its sales channels and strengthen sales process management in the upcoming period[29]. - The company is actively expanding its market presence by optimizing product structures and strengthening relationships with distributors[35]. Environmental Responsibility - The company has implemented a strategy focused on clean production and end-of-pipe treatment to enhance environmental sustainability[58]. - The company has established an emergency response plan for environmental incidents, which was reviewed and approved by the local environmental authority in November 2019[70]. - The company adheres to strict environmental standards, with maximum allowable discharge concentrations for various pollutants established[62]. - The company has not experienced any major environmental pollution incidents during the reporting period[60]. - The company has a wastewater discharge monitoring system in place, ensuring accurate data through third-party maintenance[71]. Corporate Governance and Compliance - There were significant changes in the board of directors and management, with multiple elections and appointments during the reporting period[54]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[56]. - The company has not reported any changes in the controlling shareholder or actual controller during the reporting period[103]. - The company has not received any penalties or corrective actions related to legal violations during the reporting period[92]. - The company has committed to avoiding and reducing related party transactions with its subsidiaries, ensuring fair business practices[77]. Future Outlook - The company plans to enhance its market expansion strategies, focusing on increasing its market share in key regions[132]. - Future performance guidance indicates a cautious outlook, with expectations of moderate growth in the upcoming quarters[132]. - The company is committed to improving operational efficiency and reducing costs to enhance profitability[132]. - Ongoing investments in research and development are expected to yield new technologies that will support long-term strategic goals[132]. - The company plans to implement share repurchase measures to stabilize stock prices, with a maximum repurchase amount not exceeding 2% of the total share capital[86].

第一季度财务报表是否经审计 □是 √否 2022 年第一季度报告 证券代码：603811 证券简称：诚意药业 浙江诚意药业股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 159,649,283.42 | | -6.75 | | 归属于上市公司股东的净利润 | 28,920,557.20 | | -36.91 | | 归属于上市公司股东的扣除非经常性 | 30,919,436.17 | | -33. ...

Financial Performance - The company's operating revenue for 2021 was approximately ¥693.96 million, a decrease of 8.46% compared to ¥758.13 million in 2020[22]. - Net profit attributable to shareholders for 2021 was approximately ¥170.80 million, representing a 3.42% increase from ¥165.14 million in 2020[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥156.31 million, up 4.48% from ¥149.60 million in 2020[22]. - The cash flow from operating activities decreased by 19.30% to approximately ¥143.49 million from ¥177.81 million in 2020[22]. - Total assets at the end of 2021 were approximately ¥1.32 billion, an increase of 9.58% from ¥1.21 billion at the end of 2020[22]. - The company's basic earnings per share for 2021 was ¥0.73, a 2.82% increase from ¥0.71 in 2020[23]. - The weighted average return on net assets decreased to 18.46%, down 1.90 percentage points from 20.36% in 2020[23]. - The decrease in operating revenue was primarily due to the impact of the pandemic and increased competition in the vitamin drug market, leading to a 43.39% decline in sales[23]. - The company reported a net asset value attributable to shareholders of approximately ¥986.31 million at the end of 2021, a 12.86% increase from ¥873.95 million at the end of 2020[22]. - The net profit attributable to shareholders increased slightly, primarily due to a 17.89% year-on-year increase in sales of joint-related drugs and increased performance compensation and investment income from Fujian Huakang[24]. Market Position and Product Development - The company's main product, glucosamine hydrochloride capsules, secured over 41% market share in nine provinces and cities after winning the third batch of national procurement[33]. - The company actively participated in pharmaceutical bidding across various provinces, enhancing its market presence and risk management[33]. - The company achieved a revenue of 2.93 trillion yuan in the pharmaceutical manufacturing industry in 2021, representing a year-on-year growth of 20.1%[36]. - The total profit for the pharmaceutical manufacturing industry reached 627.14 billion yuan in 2021, with a year-on-year increase of 77.9%[36]. - The company has 72 drug production approval numbers, with 41 included in the national medical insurance catalog and 14 in the national essential drug list[40]. - The company has 13 invention patents and 21 utility model patents, focusing on various therapeutic areas including arthritis, diuretics, and anti-tumor[40]. - The company has 14 new products under research, with key products like aspartate and ornithine raw materials approved[39]. - The company has established a subsidiary in Guangzhou with a registered capital of 10 million yuan, focusing on traditional Chinese medicine marketing and technology application services[35]. - The company has implemented a comprehensive quality management system, achieving GMP normalization and winning the Wenzhou Mayor Quality Award[34]. - The company has initiated consistency evaluation for 10 oral solid formulations, with key products like glucosamine hydrochloride capsules and tolvaptan injection successfully approved[34]. Research and Development - Research and development expenses rose by 24.92% to CNY 39.72 million, reflecting increased investment in outsourced R&D and personnel costs[51]. - The company is focused on expanding its product line with ongoing R&D in anti-tumor and liver protection drugs, enhancing long-term revenue growth prospects[48]. - The company’s R&D investment amounted to RMB 39.71 million, representing 5.72% of total revenue, with over 20 products under development focusing on marine drugs, geriatric medications, anti-tumor drugs, traditional Chinese medicine, and anti-infection drugs[86]. - The company has a total of 28 ongoing R&D projects, focusing on various therapeutic areas including antiviral and cardiovascular diseases[96]. - The company’s R&D strategy includes a focus on high-level protective drugs suitable for respiratory infections, which are critical in the current health landscape[90]. Sales and Marketing - The company has adopted a sales model that includes direct sales for raw materials and a distribution model for formulations, expanding its sales network despite pandemic challenges[41]. - The direct sales model saw a revenue decrease of 11.07%, with a gross margin of 56.13%[54]. - The company is expanding its sales coverage by optimizing its distribution network and enhancing management of regional distributors[99]. - The company has maintained strong relationships with high-end clients in Europe and the U.S. since 1998, ensuring trust through compliance with international regulations[100]. - A new marketing strategy has been implemented, focusing on digital channels, which is expected to increase customer engagement by 30%[126]. Corporate Governance and Compliance - The company has implemented a robust corporate governance structure to ensure compliance with legal requirements and protect shareholder rights[119]. - The company has implemented a comprehensive information disclosure management system to ensure transparency and protect shareholders' rights[120]. - The company continues to enhance its corporate governance structure and internal control mechanisms to promote sustainable development[120]. - The company has maintained compliance with legal and regulatory requirements regarding corporate governance[120]. - The company is committed to preventing insider trading and ensuring fair information disclosure practices[120]. Environmental Responsibility - The company reported no significant environmental pollution incidents during the reporting period, adhering to clean production principles[158]. - The company has implemented an online monitoring system for wastewater discharge, ensuring accurate data and compliance with environmental standards[167]. - The company has received environmental impact assessment approvals for multiple projects, including a 200-ton pharmaceutical raw material investment project and a 500-ton hydrochloric acid amino glucose raw material project[163]. - The company has established an emergency response plan for environmental incidents, which was approved in November 2019[166]. Shareholder Relations and Equity Management - The company has a cash dividend policy that has not been adjusted during the reporting period, with a total cash dividend of 58,447,200 RMB distributed based on a base of 166,992,000 shares, resulting in a dividend of 0.35 RMB per share[150]. - The proposed cash dividend for the 2021 fiscal year is 2.50 RMB per 10 shares, pending approval from the shareholders' meeting[151]. - The company has established a clear framework for share reduction that remains in effect regardless of changes in shareholder status or employment[184]. - The company has committed to stabilize stock prices through various measures, including share buybacks and shareholder increases[188]. - The company’s stock price stabilization measures will be initiated if the stock price falls below the latest audited net asset value due to non-force majeure factors[188]. Risks and Challenges - The company is facing potential risks from industry policy changes, including drug procurement and pricing reforms, which could impact sales and operational models[112]. - The company acknowledges the risks associated with new product development, including regulatory approval failures and market demand uncertainties[114]. - The company is aware of environmental risks related to production waste and is prepared to meet stricter future regulations[115].

Financial Performance - The company's revenue for Q3 2021 was ¥165,864,539.28, representing a decrease of 8.97% compared to the same period last year[5] - Net profit attributable to shareholders was ¥39,750,798.15, showing a slight increase of 0.69% year-on-year[5] - The basic earnings per share for the quarter was ¥0.17, with a year-to-date figure of ¥0.51, reflecting a 15.91% increase[7] - The net profit attributable to shareholders for the year-to-date was ¥118,099,843.50, an increase of 14.96% compared to the same period last year[5] - In Q3 2021, the company's net profit reached CNY 118,457,818.07, an increase of 15.4% compared to CNY 102,886,721.91 in Q3 2020[22] - The company's operating profit for Q3 2021 was CNY 140,375,076.96, up from CNY 121,824,787.04 in Q3 2020, indicating a year-over-year increase of 15.2%[22] - The company reported a total comprehensive income of CNY 118,461,416.90 in Q3 2021, compared to CNY 102,746,318.20 in Q3 2020, representing a growth of 15.2%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,241,285,980.39, an increase of 2.85% from the end of the previous year[7] - Total assets amounted to ¥1,241,285,980.39, compared to ¥1,206,881,405.82, representing an increase of about 2.8%[18] - Total liabilities decreased to ¥295,184,614.86 from ¥320,794,257.19, indicating a reduction of approximately 8.0%[18] - The company's equity attributable to shareholders increased to ¥933,606,736.59 from ¥873,950,854.14, reflecting a growth of about 6.8%[18] Cash Flow and Investments - The company reported a cash flow from operating activities of ¥91,717,153.63 for the year-to-date, which is a decrease of 13.76%[7] - The cash flow from operating activities for the first nine months of 2021 was CNY 91,717,153.63, down from CNY 106,345,768.07 in the same period of 2020, a decrease of 13.8%[26] - The net cash flow from investing activities was negative CNY 34,774,285.52 in Q3 2021, compared to negative CNY 276,360,741.35 in Q3 2020, showing an improvement[27] Shareholder Information - The company had a total of 15,186 common shareholders at the end of the reporting period[12] - The largest shareholder, Yan Yiyi, holds 23.58% of the shares, totaling 55,137,200 shares[12] Operating Costs and Revenue - Total operating revenue for the first three quarters of 2021 reached ¥523,732,179.68, an increase from ¥512,332,595.93 in the same period of 2020, representing a growth of approximately 4.1%[21] - Total operating costs decreased to ¥404,496,899.28 from ¥416,303,868.11, indicating a reduction of about 2.0%[21] Other Financial Metrics - The weighted average return on equity decreased to 4.35%, down 0.6 percentage points from the previous year[7] - Research and development expenses increased to CNY 29,531,472.54 in Q3 2021 from CNY 23,331,609.70 in Q3 2020, marking a rise of 26.6%[22] - Financial expenses decreased to CNY 871,393.84 in Q3 2021 from CNY 1,953,497.81 in Q3 2020, a reduction of 55.5%[22] - Short-term borrowings rose significantly to ¥89,410,653.59 from ¥40,043,000.00, an increase of approximately 123.5%[17] Accounts Receivable and Inventory - Accounts receivable rose to ¥81,328,166.34, up from ¥66,344,156.94, marking an increase of about 22.6%[16] - Inventory decreased to ¥103,208,855.86 from ¥119,256,476.27, showing a decline of approximately 13.5%[16]

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 357,867,640.40, an increase of 8.41% compared to RMB 330,119,373.07 in the same period last year[15]. - The net profit attributable to shareholders of the listed company reached RMB 78,349,045.35, reflecting a year-on-year increase of 23.87% from RMB 63,252,604.59[15]. - The net profit after deducting non-recurring gains and losses was RMB 79,129,109.39, which is a 37.11% increase compared to RMB 57,710,145.67 in the previous year[15]. - The basic earnings per share increased to RMB 0.34, up 25.93% from RMB 0.27 in the same period last year[16]. - The weighted average return on net assets rose to 8.67%, an increase of 0.56 percentage points from 8.11%[17]. - The revenue growth was primarily driven by the sales of glucosamine hydrochloride capsules, which saw a year-on-year increase of approximately 47% due to successful bidding in national procurement[17]. - The net cash flow from operating activities decreased by 13.14% to RMB 54,027,637.57, mainly due to increased tax payments compared to the previous year[15]. - The total assets at the end of the reporting period were RMB 1,237,648,494.76, representing a 2.55% increase from RMB 1,206,881,405.82 at the end of the previous year[15]. - The net assets attributable to shareholders of the listed company increased to RMB 893,879,757.88, a rise of 2.28% from RMB 873,950,854.14[15]. Research and Development - Research and development expenses increased by 38.95% to CNY 19.99 million, driven by outsourced R&D costs and direct material inputs[31]. - The company has over 20 new products in development, with one completing clinical trials and three formulations submitted for approval[28]. - The company is investing in new technology development, with a budget allocation of 15,540,604.50 for research and development activities in the current fiscal year[140]. Environmental Compliance - The company reported an average concentration of chemical oxygen demand (COD) at 28.10 mg/L, with a total discharge of 0.246 tons for the first half of 2021[44]. - The average concentration of COD for the subsidiary was reported at 59.5 mg/L, with a total discharge of 4.4 tons for the first half of 2021[45]. - The company has not experienced any environmental pollution incidents during the reporting period[43]. - The company has implemented a comprehensive emergency response plan for environmental incidents, approved in November 2019[51]. - The company has maintained compliance with pollution discharge standards, including those for wastewater and noise levels[44]. Corporate Governance and Structure - The company has established a structured governance framework, including a board of directors and various specialized committees to oversee its operations[150]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial statements accurately reflect its financial position and operating results[157]. - The company confirmed that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[155]. Shareholder and Capital Management - The total share capital after the distribution is 233.79 million shares, with a cash dividend of 0.35 CNY per share, totaling 58.45 million CNY distributed[92]. - Shareholders and management commit to a lock-up period of 12 to 36 months for their shares post-IPO, with specific conditions for share reduction thereafter[72][73][75]. - The controlling shareholder, Yan Yiyi, commits to not transferring more than 25% of his shares annually during his tenure and not transferring any shares within six months after leaving the position[77]. Market Strategy and Expansion - The company is actively expanding its marketing network and enhancing its sales team to adapt to market changes and achieve strategic marketing goals[30]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters, aiming for a targeted growth rate of 10%[135]. - The company has identified potential acquisition targets to enhance its market share and diversify its product portfolio, with a focus on strategic partnerships[135]. Financial Instruments and Reporting - The company emphasizes the importance of accurate financial reporting and compliance with accounting standards in the recognition and measurement of financial instruments[176]. - Financial assets are derecognized when the contractual rights to cash flows expire, the asset is transferred and substantially all risks and rewards are transferred, or control over the asset is relinquished[184]. - The company recognizes expected credit losses for held-for-sale assets based on the likelihood of sale and binding purchase commitments[200].

证券代码：603811 证券简称：诚意药业 公告编号：2021-027 浙江诚意药业股份有限公司 关于投资者接待日活动情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步提高企业治理水平，增进公司与广大投资者之间的信息沟通，公司 于 2021 年 4 月 28 日举办了投资者接待日活动，管理层就公司经营情况、发展战 略等与广大投资者进行了充分交流，同时解答了投资者较为关注的问题。具体情 况如下： 一、活动基本情况 1、活动时间：2021 年 4 月 28 日 15:00-17:00。 2、活动地点：上海虹桥商务区凯悦嘉轩酒店，二楼会议厅：3&5 3、出席人员： ⑴公司出席人员：副董事长任秉钧先生、总经理赵春建先生、副总经理罗飞 跃先生、副总经理张志宏先生、副总经理吕志东先生、副总经理兼董事会秘书柯 泽慧女士、财务总监吕孙战先生等。 | --- | --- | |---------------|--------------------------------------| | 4、活动日程： | | | 时 ...